Celcuity (CELC) is trading higher as the market continues to price in its near-term regulatory catalyst: the FDA granted Priority Review to the company’s New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer and set a PDUFA goal date of July 17, 2026. With the decision less than three months away, the stock is seeing continued speculative accumulation tied to the binary approval setup and potential launch timeline. (investing.com)

Priority Review compresses the FDA’s review timeline and signals the agency views the application as addressing an area of meaningful unmet need. For Celcuity, it brings the company into a defined window where sentiment and positioning can swing quickly on any regulatory or review-process updates, including labeling discussions, manufacturing readiness, or an earlier-than-expected action. The company has also highlighted its intent to be ready to launch soon after approval if the decision is positive. (finance.yahoo.com)

Celcuity is being valued primarily on the probability-weighted outcome of gedatolisib’s first potential approval and commercialization ramp. The July 17, 2026 decision date acts as a hard catalyst that can tighten the trading range into the event, amplify moves on incremental news, and keep attention elevated across the biotech tape as investors rotate into defined regulatory timelines. (investing.com)

Near-term focus is on any FDA communications that could affect timing (including requests for additional information, potential advisory committee scheduling, or updates tied to review status), plus Celcuity’s launch-prep disclosures and financing posture as it approaches a commercial transition. The stock’s volatility can remain elevated into mid-July given the binary nature of FDA outcomes and the market’s tendency to crowd into high-profile PDUFA setups. (ir.celcuity.com)